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the CC BY-NC-ND license (http://creaAbstract For a patient suffering from non-metastatic prostate cancer, the individualized
recommendation of radiotherapy has to be the fruit of a multidisciplinary approach in the
context of a Tumor Board, to be explained carefully to the patient to obtain his informed con-
sent. External beam radiotherapy is now delivered by intensity modulated radiotherapy,
considered as the gold standard. From a radiotherapy perspective, low-risk localized prostate
cancer is treated by image guided intensity modulated radiotherapy, or brachytherapy if pa-
tients meet the required eligibility criteria. Intermediate-risk patients may benefit from inten-
sity modulated radiotherapy combined with 4e6 months of androgen deprivation therapy;
intensity modulated radiotherapy alone or combined with brachytherapy can be offered to pa-
tients unsuitable for androgen deprivation therapy due to co-morbidities or unwilling to accept
it to preserve their sexual health. High-risk prostate cancer, i.e. high-risk localized and locally
advanced prostate cancer, requires intensity modulated radiotherapy with long-term
(2 years) androgen deprivation therapy with luteinizing hormone releasing hormone agonists.
Post-operative irradiation, either immediate or early deferred, is proposed to patients classi-
fied as pT3pN0, based on surgical margins, prostate-specific antigen values and quality of life.
Whatever the techniques and their degree of sophistication, quality assurance plays a major
role in the management of radiotherapy, requiring the involvement of physicians, physicists,
dosimetrists, radiation technologists and computer scientists. The patients must be informed
about the potential morbidity of radiotherapy and androgen deprivation therapy and followed
regularly during and after treatment for tertiary prevention and evaluation. A close coopera-
tion is needed with general practitioners and specialists to prevent and mitigate side effects
and maintain quality of life.ble.fr (M. Bolla).
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licenses/by-nc-nd/4.0/).1. Intensity modulated radiotherapy,
hypofractionated radiotherapy and
stereotactic radiotherapy
1.1. Intensity modulated radiotherapy
Intensity-modulated radiotherapy (IMRT) is the standard of
care for external beam radiotherapy (EBRT) as regards
localized, locally and regionally advanced prostate cancer
(PCa). Individual collimator leaves move during the period
of radiotherapy exposure, sculpting the computed tomog-
raphy (CT) based planning target volume, resulting in a
concave surface to increase the anatomical conformity and
enable dose escalation (Fig. 1). Planning must be accom-
panied by quality assurance; details of volume, and dose
constraints should be defined per protocol, and compliance
assured with dose-volume histograms. Treatment verifica-
tion is essential, and IMRT is often combined with some
form of image-guided radiotherapy (IGRT), in which the
prostate/target volume’s position is verified by imaging
during a treatment exposure. IMRT may also be applied to
irradiation of pelvic lymph nodes in case of high risk PCa or
regionally advanced PCa. Based on the results of five pub-
lished randomized clinical trials, dose escalation improves
biochemical and local control [1], and overall survival ac-
cording to a non-randomised well conducted propensity
matched retrospective analysis of the United States Na-
tional Cancer Database covering a total of 42 481 patients:
There is a benefit for intermediate-risk (p < 0.001) and
high-risk PCa (p < 0.001) but not for low-risk (pZ 0.54) [2].
For clinically localized PCa the ProtecT trial comparing
active monitoring, radical prostatectomy and EBRT, has
shown at a median follow-up of 10-year, that the PCa
specific mortality was identical for radical prostatectomyintensity-modulated radio-
d, conformal radiotherapy
roved dose distribution and
RT. Courtesy of Dr Garethand three-dimensional (3D) conformal radiotherapy deliv-
ered at a dose of 74 Gy in 37 fractions with neo adjuvant
androgen deprivation therapy (ADT) for 3e6 months [3]; of
note, IMRT with further dose escalation, or brachytherapy
were not performed.
The European Association of Urology (EAU) guidelines
recommend a total dose of 74e78 Gy in low-risk patients
(LE 1a, GR A), 76e78 Gy in combination with short-term
ADT (4e6 months) in intermediate-risk patients (LE 1b GR
A) when radiotherapy is given in standard fraction sizes of
1.8e2 Gy per fraction [1].
1.2. Hypofractionation (HFX)
HFX is the use of larger than standard fraction sizes of
EBRT, with two modalities: Either moderate with dose per
fraction 5 Gy or extreme with dose per fraction 5 Gy.
The rationale is that tissues which are prone to late radi-
ation damage (therefore permanent) such as the spinal
cord, are more sensitive to large doses per fraction, and
PCa is believed to behave like such late-reacting tissues [4].
The emerging evidence for improved disease control with
dose escalation gave new impetus to HFX, taking the total
dose beyond what was the standard.
1.2.1. Moderate dose-escalated HFX
According to a recent review [5] merging studies [6e8]
using various techniques and in part including ADT, mod-
erate HFX delivered with conventional 3D conformal
radiotherapy  IMRT has sufficient follow-up to give
credence to its safety, while awaiting long-term results.
Table 1 summarizes mature data of trials not powered to
report on superiority in terms of efficacy, many being non-
inferiority trials and powered as such. The trials are re-
ported in two distinct phases. In the first phase, safety is
the main concern, and non-inferiority is absolutely the
appropriate endpoint; the studies vary according to
whether toxicity is based on physician-administered scales,
such as the Radiation Therapy Oncology Group (RTOG)
grade, or whether it is from a patient-administered scale
such as expanded prostate cancer index composite. The
second phase would be the reporting of efficacy, reported
as disease-free survival, or biochemical control. The largest
trial reporting on disease free survival is the RTOG 0415
trial, a noninferiority trial, with 1115 men randomised, all
of whom had low risk disease; at a median follow-up of 5.8
years the disease-free survival was consistent with the pre-
defined criteria for noninferiority, however there were
more late genitourinary (GU) adverse events in patients
treated with hypofractionated radiotherapy [9]. The non
inferiority CHHIP trial, randomized 3216 men to EBRT with
conventional (74 Gy in 37 fractions over 7.5 weeks) versus
hypofractionated (60 Gy in 20 fractions over 4 weeks or
57 Gy in 19 fractions over 3.8 weeks). The 5-year outcomes
Table 1 Major phase III randomised trials of moderate hypofractionation for primary treatment.
Study/Author n Risk, GS, or NCCN ADT RT regimen BED, Gy Median FU,
month
Outcome
Lee et al. [9] 550
542
low risk None 70 Gy/28 fx
73.8 Gy/41 fx
80
69.6
70 5 year DFS 86.3% (n.s.)
5 year DFS 85.3%
Dearnaley et al. [10] 1077/19 fx
1074/20 fx
1065/37 fx
15% low
73% intermediate
12% high
3e6 months,
before and
during EBRT
57 Gy/19 fx
60 Gy/20 fx
74 Gy/37 fx
73.3
77.1
74
62 5 year BCDF
85.9% (19 fx)
90.6% (20 fx)
88.3% (37 fx)
Aluwini et al. [6] 403
392
30% GS <6,
45% GS >7,
25% GS 8e10
None 64.6 Gy/19 fx
78 Gy/39 fx
90.4
78
60 5 year RFS 80.5% (n.s.)
5 year RFS 77.1%
Catton et al. [11] 608 intermediate risk
53% T1c
46% T2a-c
None 60 Gy/20 fx 77.1 72 5 year BCDF
both arms 85%
HR: 0.96 (n.s)
598 9% GS 6
63% GS 7a
28% GS 7b
78 Gy/39 fx 78
ADT, androgen deprivation therapy; BCDF, biochemical or clinical disease failure; BED, biologically equivalent dose, calculated to be
equivalent in 2 Gy fractions using an a/b of 1.5 Gy; DFS, disease-free survival; EBRT, external beam radiotherapy; FU, follow-up; fx,
fractions; GS, Gleason score; HR, hazard ratio; NCCN, National Comprehensive Cancer Network; n.s., not significant; RFS, relapse free
survival; RT, radiotherapy.
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74 Gy schedule [10]. Another multicenter randomized non
inferiority trial in intermediate-risk PCa [11] comparing
78 Gy in 39 fractions over 8 weeks to hypofractionated RT of
60 Gy in 20 fractions over 4 weeks has concluded that the
hypofractionated RT regimen was not inferior to conven-
tional RT but was associated with increased late toxicity.
The EAU guidelines state that moderate HFX including
IGRT to the prostate only, can be offered to carefully
selected patients with localised disease (LE 1a, GR A).
Moderate HFX should adhere to RT-protocols from trials
with equivalent outcome and toxicity, i.e. 60 Gy/20 frac-
tions in 4 weeks or 70 Gy/28 fractions in 6 weeks. (LE 1a, GR
A) [1].
1.3. Stereotactic radiotherapy
Stereotactic radiotherapy is characterized by i) extremely
accurate patient positioning, as it is achieved in neuro-
oncology by using a frame that was physically attached to
the patient’s skull; ii) meticulously accurate radiotherapy
planning to define a very small high dose volume; iii) de-
livery of radiation using a very small “pencil” beam, and
multiple fields to provide adequate coverage of the target.
These principles were modified in the Cyberknife by
creating a free-standing, robotic linear accelerator head,
which could deliver a pencil beam of radiation, and was
capable of being orientated in any plane of rotation, able to
do so isocentrically. As there is no treatment frame
attached to the patient, the machine head must be capable
of adjusting rapidly to any changes in patient position. The
system is therefore combined with on-board image-guided
localisation, with fiducial markers inserted into the pros-
tate. It is possible to deliver stereotactic radiotherapy with
a state-of-the-art Linac with full IMRT/IGRT capabilities,
which has become a preferred option in some centres,because the equipment can be used in a variety of
indications.
1.3.1. Extreme hypofractionation
Stereotactic radiotherapy allows extreme HFX as part of a
formal clinical trial in the treatment of localised PCa, since
there have been no randomised trials comparing extreme
HFX to other schedules. It is used in a number of centres, on
the basis of its practical advantages, and based on the re-
sults of nonrandomised case series [5,11,12]. The largest
and most mature series of nonrandomised patients had
been reported by Zaorsky et al. [13] concerning 324 low-risk
and 153 intermediate-risk patients treated with Cyber-
knife; following treatment with either 35 or 36.25 Gy
delivered in five fractions: 7-year biochemical disease-free
survival were 95.6% and 89.6% for low and intermediate-risk
patients, respectively. Caution is needed in inter-
pretationdthe selection criteria for patients vary, in some
instances which are difficult to ascertain, patients with
predominantly, less than high grade diseasedand the same
outcomes might not be attainable in a less selected
population.
EAU guidelines regard extreme HFX as being experi-
mental, to be delivered in specialised centres in the
context of a formal clinical trial; as a minimum, outcome
data in terms of patient-reported toxicity and quality of
life, plus oncological outcomes, should be recorded and
published.
2. Permanent and high dose brachytherapy
Brachytherapy is a form of radiotherapy where a sealed
radiation source is placed directly into the body. The
placement of radiation sources in the prostate can be
permanent or temporary. Permanent interstitial brachy-
therapy or seed brachytherapy, involves placing low dose
156 M. Bolla et al.rate (LDR) radioactive sources into the prostate and leaving
them permanently to gradually release radiation over time.
Temporary brachytherapy involves first placing needles or
catheters within the prostate and, on confirmation of ac-
curate positioning, temporarily introducing the radioactive
source into the prostate. Radiation is delivered using a high
dose rate (HDR) machine where actual treatment times are
minutes. A comparison of LDR and HDR prostate brachy-
therapy treatments is listed in Table 2.
Prostate brachytherapy is often done as a day-case
under general or regional anaesthesia. The patient is
placed in the lithotomy position and trans-rectal ultrasound
(TRUS) is used to provide image guidance. For permanent
brachytherapy, treatment may be done either as a two-step
procedure, where the TRUS pre-plan takes place a few
weeks before actual implantation, or as a single-step pro-
cedure, where the plan is created in the operating room
and seeds inserted in real-time. HDR treatment planning
can be undertaken in real-time in theatre using ultrasound
or alternatively, and the patient can be woken up and CT or
magnetic resonance imaging (MRI) acquired to identify the
target volume and plan source delivery. Where multiple
HDR treatments are used, the catheters can stay in situ and
are used to deliver fractionated treatments; following ra-
diation delivery the HDR needles/catheters are removed.
Detailed European Society of Therapeutic Radiation
Oncology (ESTRO) guidelines on the clinical and technical
aspects of both permanent and HDR brachytherapy are
recommended and centres should follow strict quality
assurance guidelines [14,15]. Men with pre-existing urinary
symptoms are at high risk of retention after brachytherapy
and/or experiencing prolonged urinary symptoms. The In-
ternational Prostate Symptom Score (IPSS) can be used to
screen patients with a score <9 being ideal and scores <15
acceptable [16]. Urinary flow tests are more objective. Men
with peak urinary flow rates of <10 mL/s have a 30% risk ofTable 2 Comparison of prostate brachytherapy techniques.
Comparison of prostate brachytherapy techn
LDR - Permanent seeds implanted at single visit
- Uses Iodine-125 (most common), Palladium
- Radiation dose delivered over weeks and m
- Acute side effects resolve over months
- Radiation protection issues for patient and
- shielded theatre room
- Established as monotherapy for low and se
- Established as a boost treatment with exte
cancer
HDR - Temporary implantation and may need to
- Ir-192 (most common) Co-60 source introd
- Radiation dose delivered in minutes
- Acute side effects resolve over weeks
- No radiation protection issues for patient
- Can use same HDR source for other cancer
- Need for a shielded HDR treatment room
- Established as boost treatment with extern
cancer
- Single centre cohort studies demonstrate g
LDR, low dose rate; HDR, high dose rate.post-implant retention and brachytherapy is generally not
advised. Those with peak flow rates >20 mL/s have <10%
risk of catheterization and are good candidates for
brachytherapy [17]. Neo-adjuvant androgen deprivation for
3e6 months can be used to downsize the prostate in pa-
tients with enlarged glands.
Post-implantation side effects are predominantly urinary
and are very common in the first weeks after treatment.
Urinary symptoms are relieved by a-blockers and anti-
inflammatories will help with pain and discomfort. Acute
retention can occur in 10%e20% and is managed by cathe-
terisation. Rectal side effects are usually mild. The use of
brachytherapy boost with EBRT is associated with more GU
side effects when compared to EBRT alone [18].
2.1. LDR brachytherapy
Patients with low risk localised PCa (clinical T1c-T2a,
Gleason score 6, <50% core positive, prostate-specific an-
tigen [PSA] <10 ng/mL) and selected patients with low
volume intermediate risk localised prostate cancer (clinical
T1c-T2a, Gleason score 3 þ 4, PSA <10 ng/mL, <33% core
positive) are suitable for permanent prostate brachyther-
apy alone. The biochemical control for low risk patients
after 5 and 10 years has been reported to range from 71% to
93% and 65% to 85%, respectively [1].
In patients with higher risk disease there is a significant
risk of extra-capsular spread that may not be included in
the high dose region of a seed implant. In this situation
brachytherapy may be combined with EBRT to ensure an
appropriate target is treated. In the ASCENDE-RT trial, LDR
boost resulted in improved PSA control when compared to
EBRT alone but at the cost of higher GU late toxicity [19].
Approximately 50% of the GU toxicity was due to urethral
strictures and a boost dose of 110 Gy rather than 115 Gy
should be used.iques
-103 or Caesium-131 isotopes
onths
carers
lected intermediate risk localized prostate cancer
rnal beam radiation in higher risk or locally advanced prostate
be fractionated
uced through implanted applicators (needles or catheters)
or carers
treatments
al beam radiation in higher risk or locally advanced prostate
ood outcomes when used as monotherapy for localised disease
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HDR brachytherapy is established as a boost treatment with
EBRT but there is no consensus regarding the timing of HDR
brachytherapy in relation to EBRT, EBRT volumes and either
EBRT or HDR dose schedules. HDR brachytherapy as a boost
has been prescribed with schedules including 15 Gy in three
fractions, 11e22 Gy in two fractions and 12e15 Gy in one
fraction [16]. HDR monotherapy has been investigated in
cohort studies using schedules varying from a single to up to
nine fractions. In localized disease excellent PSA control is
achieved with low rates of gastro-intestinal side effects [20].
The recommendation of the EAU guidelines is that in
patients with low-risk PCa and selected intermediate-risk
PCa, without a previous transuretral resection and with a
good IPSS and a prostate volume <50 mL, LDR brachyther-
apy can be offered (LE 2a, GR A).
3. Post-operative radiotherapy: Immediate or
early delayed
In high-risk PCa, the likelihood of local relapse rate rises in
case of poor prognostic risk factors. Immediate (adjuvant)
postoperative radiotherapy (ART) or early delayed (salvage)
radiotherapy (SRT) has to be discussed as part of a multi-
modal approach and the decision should be explained by
the urologist to the patient before surgery.
3.1. Adjuvant radiotherapy
Three randomized clinical trials SWOG 8794 [21], EORTC
22911 [22] and ARO 96-02 [23] where an undetectable PSA
was required after radical prostatectomy (RP), have shown
that ART realized 4 months after RP reduces significantly the
10-year rate biochemical relapse and may improved 10-year
overall survival (p Z 0.02) [21] with respect to RT delayed
until local recurrence. The greatest benefit from ART is ob-
tained in men with pT3 and positive surgical margins or
Gleason score 7e10 as additional risk factor. The dose was
60e64 Gy and in the ARO 96-02 study which exclusively
utilized 3D-based treatment planning, the incidence of late
grade 3 or higher adverse events was only 0.3% [24].
For patients classified as pT3pN0with an undetectable PSA
level and a high risk of local failure after RP (positive surgical
margins multifocal or unifocal>2 mm, capsule rupture, and/
or invasionof the seminal vesicles) twooptions canbeoffered:
- ART to the surgical bed after recovery of urinary func-
tion (LE 1a, GR A).
- Clinical and biological monitoring followed by SRT
before the PSA exceeds 0.5 ng/mL (LE 1b, GR A), since
the biochemical disease free survival decreases signifi-
cantly beyond this threshold [25].
3.2. SRT with or without ADT for PSA only
recurrence
For patients who have a detectable PSA level
(>0.1 ng/mL) 3 months after RP or who develop a
biochemical relapse after RP as defined by a PSAvalue > 0.2 ng/mL and rising, SRT of the prostate bed
may offer a possibility of cure with a dose of at least
66 Gy [1]. More than 60% of patients treated before the
PSA level rises to values >0.5 ng/mL, will achieve an
undetectable PSA level, providing patients with 80%
chance of being progression free 5 years later [26]. The
correlation of the pre-SRT PSA level and SRT dose with
biochemical relapse shows that there was an average
2.6% loss of relapse free survival for each incremental
0.1 ng/mL PSA at the time of SRT [26]. The randomized
SAKK 09/10 trial devoted to SRT has randomly allocated
350 patients between 64 Gy and 70 Gy, with 44% con-
ventional 3D-SRT and 56% IMRT/rotational technique in
both arms. Acute GU and gastrointestinal (GI) toxicities
were mostly mild, with 3 (vs. 1) GU and 4 (vs. 1) GI
events for the dose escalation arm [27].
Addition of ADT to SRT improves outcomes. The GETUG-
AFU 16 trial comparing RT alone (66 Gy prostate with or
without 46 Gy pelvis) versus the same RT regimen þ
6-month luteotrphin hormone releasing hormone (LHRHa),
reported with a median follow-up of 63 months an
improved 5-year progression free survival in favour of the
combined approach (p < 0.0001) [28]. The RTOG 96-01
trial has compared RT þ bicalutamide (150 mg daily) for
24 months versus RT (64.8 Gy) þ placebo and has shown an
improvement of the 10-year overall survival (82% vs. 78%,
p Z 0.04) [29].
3.3. Comparison of ART and SRT
Three randomized phase III trials are assessing the role of
ART versus SRT together with the efficacy of ADT: RADICALS
(United Kingdom), RAVES (TROG) and GETUG 17 (France). In
the meantime, we can consider the 5-year results of a non-
randomised well conducted propensity matched retro-
spective analysis comparing 390 ART to 390 SRT which
showed that early SRT did not impair the biochemical dis-
ease free survival [30].
4. Combination of ADT and external irradiation
for high-risk PCa
To improve the overall survival of high-risk localized PCa or
locally advanced PCa (T3-4 N0-X M0, cN1-pN1 M0) the
combination of a local-regional EBRT with long-term ADT is
imperative to potentiate the radiation effect and to try to
eradicate microscopic sub-clinical distant metastases
outside the target volume. Randomized phase III trials have
promoted the combination of long-term adjuvant ADT
(2 years) as a standard of care.
4.1. Randomized phase III trials of use and duration
of ADT in combination with EBRT (Table 3)
The most powerful conclusion from these trials comes from
EORTC trial 22863, which is the basis for the combination of
EBRT and ADT as standard practice [31]. ADT starts either at
the onset of EBRT, or 2e3 months before to induce size
reduction of the prostate and improve lower urinary tract
symptoms, the concomitant component remaining crucial
Table 3 Major phase III randomized trials of use and duration of ADT in combination with RT for PCa.
Trial Year TNM stage n Trial ADT RT Effect on OS
EORTC 22863 [31] 2010 T1-2 poorly differentiated
and M0, or T3-4 N0-1 M0
415 EBRT  ADT LHRHa for 3 years
(adjuvant)
70 Gy RT Benefit at 10-year for combined
treatment (p Z 0.0004)
RTOG 85-31 [32] 2005 T3 or N1 M0 (15% RP) 977 EBRT  ADT Orchiectomy
or LHRHa
65e70 Gy RT Benefit for combined treatment
(p Z 0.002) mostly caused by
patients with Gleason score 7e10
D’Amico [7e10] 2008 T2 N0 M0 (localised
unfavourable
risk)
206 EBRT  ADT LHRHa plus flutamide
for 6 mo.
70 Gy
3D-CRT
Significant benefit (p Z 0.01) that
may pertain only to men with no or
minimal comorbidity
TROG 96-01 [39] 2011 T2b-4 N0 M0 802 Neoadjuvant
ADT duration
LHRHa plus flutamide
3 or 6 mo.
before, plus
concomitant
66 Gy
3D-CRT
Benefit in PCa-specific survival
(p Z 0.04)
RTOG 94-13 [40] 2007 T1c-4 N0-1 M0 1292 ADT timing comparison 2 mo. neoadjuvant
plus concomitant
vs. 4 mo.
adjuvant
Whole pelvic RT vs.
prostate only;
70.2 Gy
No significant difference between
neoadjuvant plus concomitant vs.
adjuvant
androgen suppression
therapy groups (interaction
suspected)
RTOG 86-10 [38] 2008 T2-4 N0-1 456 EBRT  ADT LHRHa plus flutamide
2 mo. before, plus
concomitant
65e70 Gy RT No significant difference at 10
year
RTOG 92-02 [33] 2008 T2c-4 N0-1 M0 1554 Short vs. prolonged
ADT
LHRHa given for 2
years as adjuvant
after 4 mo. as
neoadjuvant
65e70 Gy RT 10-year OS benefit in subset with
Gleason 8e10 for long-term ADT
(p Z 0.006)
EORTC 22961 [34] 2009 T1c-2ab N1
M0, T2c-4
N0-1 M0
970 Short vs. prolonged
ADT
LHRHa for 6 mo. vs.
3 years
70 Gy
3D-CRT
Better 5-year OS with 3-year
treatment (p Z 0.006)
SPCG-7/SFUO-3 [35] 2014 T1b-2 Grade
2e3, T3 N0 M0
875 ADT  EBRT LHRH a for 3 mo plus
continuous
flutamide
70 Gy
3D-CRT vs. no RT
Lower 15-year cancer specific
mortality (30.7%) vs. (12.4%)
favouring combined treatment
(p < 0.0001)
NCIC CTGMRC/PR3/
PRO7/SWOG [36]
2015 T3-4 (88%),
PSA >20 ng/mL (64%), GS 8e10
(36%) N0 M0
1205 ADT  EBRT Continuous
LHRHa
65e70 Gy
3D-CRT vs. no RT
10-year OS benefit for combined
treatment (p < 0.001)
French study [37] 2012 T3-4 N0 M0 273 ADT  EBRT LHRHa for 3 year 70 Gy
3D-CRT vs. no RT
Better 5-year progression free
survival for combined treatment
(p < 0.001)
264
ADT, androgen deprivation therapy; 3D-CRT, three-dimensional conformal radiotherapy; EBRT, external beam radiotherapy; GS, Gleason score; HR, hazard ratio; LHRHa, luteinising-
hormone-releasing hormone agonist; mo., months; OS, overall survival; PCa, prostate cancer; RT, radiotherapy.
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Radiotherapy in front of localized prostate cancer 159to potentiate EBRT. For long-term ADT, the results of phase
III randomized trialsdEORTC 22863 [31], RTOG 85-31 [32],
RTOG 92-02 [33], EORTC 22961 [34], SPCG-7/SFUO-3 [35],
NCIC/MRC PR3/PR07 [36], and French study [37] are dis-
played in Table 3, as are those related to short term ADT:
RTOG 86-10 [38], TROG 96-01 [39], and RTOG 94-13 [40].
The EAU guidelines state that in patients with high risk-
localized PCa, the use of a total dose of 76e78 Gy (when
given in standard fraction sizes of 1.8e2 Gy per fraction) in
combination with long-term ADT (2e3 years) is recom-
mended (LE 1a, GR A) while EBRT is offered in combination
with long-term ADT (2e3 years) in patients with locally
advanced cN0 PCa (LE 1a, GR A).
4.2. Pelvic lymph-node irradiation combined with
ADT
There is no level 1 evidence for prophylactic whole pelvic
irradiation but this modality could be recommended since
pelvic lymph-node irradiation was performed for EORTC
and RTOG trials. The pelvic lymph-node target volume must
cover the nodes overlying the external iliac artery and vein,
the nodes within the obturator fossa located cranially and
caudally to the obturator nerve, and the nodes medial and
lateral to the internal iliac artery; with IMRT, pre-sacral
nodes can be included easily. Clinical or pathological node-
positive (Nþ) patients do not always develop a systemic
disease and many datadRTOG trial 85-31 [41], an homo-
geneous matched patients cohorts [42], United States Na-
tional Cancer Data Base [43], STAMPEDE Trial [44]dsuggest
that the combination of whole pelvic irradiation plus im-
mediate long-term ADT may be beneficial.
The EAU guidelines recommend that in patients with
cNþ or pNþ PCa pelvic irradiation can be offered in com-
bination with immediate long-term ADT (LE 2b, Grade B) [1].
4.3. Side effects
ADT with LHRHa may induce hot flushes, fatigue, weight
gain, loss of libido and erectile dysfunction, insulin resis-
tance, lower bone mineral density with an increase risk of
bone fracture, increased cardiovascular events, metabolic
syndrome, anaemia and impact on cognitive function.
These side effects, as assessed by a self-administered
questionnaire, will impact on a varying degree with the
prevalent comorbidities of the patients and the duration of
the treatment [45]. Retrospective analyses of the EORTC
and RTOG have shown that long-term ADT did not increase
the cumulative incidence estimates of cardiovascular
mortality as compared with short-term or no
ADT [32,35,46,47]. Overweight status is associated with
PCa mortality in men undergoing combined treatment, and
prevalent diabetes is associated with greater all-cause and
non PCa mortality [48]. Many studies demonstrated that
long-term ADT was associated with an increased risk of
fractures and prevention of bone mineral loss through
lifestyle modification is recommended, as well as the use of
bisphosphonates in case of osteoporosis [49]. These po-
tential side-effects have to be discussed with patients to
evaluate the risk-benefit ratio, taking into accountdage,
WHO performance status, co-morbidities, sexual health,lifestyle, tobacco usage and body mass indexdto enable
them to mitigate adverse effects by stopping smoking,
reducing their weight, improving diet and increasing phys-
ical exercise. To reduce the risk of adverse effects, other
parameters should be assesseddglycemia, hyperlipidemia,
use of blood pressure medication or oral anticoagulation,
control of bone mineral densitydso that comorbidity
treatments are adjusted appropriately by general practi-
tioners, endocrinologists and cardiologists.
4.4. New modalities of ADT
A better understanding of androgen receptor signaling and
mechanism underlying resurgent androgen receptor activity
has induced major breakthroughs in the development of
novel androgen-ablative and androgen receptor antagonist
strategies to more effectively inhibit receptor activity [50].
The third generation gonadotrophin hormone releasing
hormone antagonist degarelix is being used in advanced
PCa and its definitive superiority over LHRH analogues re-
mains to be proven by on going randomized phase III trials.
Abiraterone acetate, a potent and selective inhibitor of
CYP 17denzyme required for androgen biosynthesis in the
testes, adrenal glands, and prostate tissuedis investigated
in randomized phase III trials with LHRH agonist and EBRT
for high risk PCa. Enzalutamide, a novel androgen receptor
antagonist that binds the androgen receptor and prevents
both androgen receptor translocation and DNA binding, is
investigated with LHRH agonists and EBRT for high risk PCa.
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